Unknown PHASE3 INTERVENTIONAL 2-arm NCT00957086

Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer

Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer

Sponsor: Innogene Kalbiotech Pte. Ltd

Conditions Carcinoma, Squamous Cell of Head and Neck

Interventions Nimotuzumab Placebo

Updated 12 times since 2017 Last updated: Jan 8, 2024 Started: Aug 13, 2009 Primary completion: Jan 1, 2025 Completion: Jan 1, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00957086, this PHASE3 trial focuses on Carcinoma, Squamous Cell of Head and Neck and remains ongoing. Sponsored by Innogene Kalbiotech Pte. Ltd, it has been updated 12 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

12 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE3

Status: Active Not Recruiting → Unknown
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Feb 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

▶ Show 7 earlier versions

May 2022 — Feb 2024 [monthly]

Active Not Recruiting PHASE3
May 2021 — May 2022 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2021 — May 2021 [monthly]

Recruiting PHASE3
Sep 2018 — Jan 2021 [monthly]

Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Apr 2018 [monthly]

Recruiting PHASE3

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innogene Kalbiotech Pte. Ltd
National Cancer Centre, Singapore
National Medical Research Council (NMRC), Singapore

Data source: National Cancer Centre, Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, Egypt , Bangalore, India , Bangkok, Thailand , Bedford Park, Australia , Cairo, Egypt , Chiang Mai, Thailand , Durban, South Africa , Gyeonggi-do, South Korea , Incheon, South Korea , Jakarta, Indonesia and 16 more locations